*Pseudomonas aeruginosa (P. aeruginosa)* is one of the most common causes of healthcare-related infections \[[@CIT0001]\]. The ST235 high-risk clone of *P. aeruginosa* has high capacity to acquire antibiotic resistance and is disseminating worldwide. The ST235 clone harbours nearly 39 types of beta-lactamases especially IMP, NDM and VIM type Metallo-β-lactamases (MBLs) \[[@CIT0002]\]. However, up to date, there is no report on co-existence of NDM-1 and OXA-48 in *P. aeruginosa*. Colistin resistance among *P. aeruginosa* is rare (\<1%) in Europe \[[@CIT0003]\]. However, it was found to be 7.4% in Korea, and 8.8% in Turkey \[[@CIT0004],[@CIT0005]\]. Dissemination of colistin resistance in high-risk clones is concerning because of increased fatality and lack of antimicrobial therapy options. The overexpression of *phoPQ* and *pmrAB* two-component regulatory systems contribute colistin resistance by reducing the negative charge of the outer membrane in *P. aeruginosa* \[[@CIT0006]\].

In this correspondence, we presented 11 cases with colistin-resistant *P. aeruginosa* infection and reported the presence of OXA-48 along with NDM-1 in the isolates belonging to the ST235 high-risk clone. We also analysed mutations and expressions of *phoPQ* and *pmrAB* systems in 11 colistin-resistant *P. aeruginosa* isolates.

Patients who were diagnosed with colistin-resistant *P. aeruginosa* infection or colonization in the ICU unit of a Cardio-Pulmonary Surgery Hospital in Istanbul between July 2017 and December 2018 were included in the study. The demographic and clinical data were recorded on a standardized case form. The patients were followed up for clinical outcomes.

The colistin resistance was determined by the broth microdilution method according to EUCAST criteria \[[@CIT0007]\]. In strain typing, Multilocus sequence typing (MLST) was performed by amplifying seven housekeeping genes, according to the protocol on Pseudomonas aeruginosa MLST website (<https://pubmlst.org/P.aeruginosa/>). Allelic profiles and sequence types (STs) were determined using Applied Math Bionumerics V7.6 software. Clonal relatedness was determined by the repetitive PCR (rep-PCR) (Diversilab, Biomerieux). Isolates that had a similarity index \>95% were considered as clonally related. Carbapenem and colistin resistance genes *(bla*~IMP~, *bla*~VIM~, *bla*~OXA~, *bla*~NDM~, *bla*~KPC~, *mcr-1*) were screened by PCR using primers as described previously, and the amplicons were confirmed by sequencing (6). For colistin resistance mechanisms, mutations in *pmrAB* and *phoPQ* were detected by Sanger Sequencing \[[@CIT0006]\]. Expressions of *pmrA* and *phoP* were studied by qRT-PCR \[[@CIT0006]\]. The *rpsl* was selected for normalization and *P. aeruginosa* ATCC 27853 was for calibration.

Among 11 patients, eight (72.7%) had an invasive infection and three (27.3%) had colonization with colistin-resistant *P. aeruginosa*. Eight (72.7%) patients stayed in ICU and six (54.5%) had lung transplantation. Sepsis was diagnosed in three (37.5%) of eight patients. The 30-day mortality rate was 88% (7/8). The overall mortality of *P. aeruginosa* infections in the hospital was 46% and it was 68% for carbapenem-resistant colistin susceptible *P. aeruginosa* infections. In a recent report from Spain, the overall 30-day mortality of bacteremia cases caused by ST235 was found to be 82%, however, it was 42.2% in other clones \[[@CIT0010]\]. In our study, the eight of 11 (72.7%) isolates belonged to *P. aeruginosa* ST235 high-risk clone. The three isolates were identified as a novel allele (ST3078) referred by Pasteur Institutes MLST database (<https://pubmlst.org/paeruginosa/>)([Table 1](#T0001){ref-type="table"}). In Germany, the mortality rate of *P. aeruginosa* bacteremia was reported as 26% in 937 ICU units \[[@CIT0008]\]. The increased mortality rates are associated with multidrug resistance \[[@CIT0009]\]. The ST235 is associated with MDR or PDR profile and fatal infections \[[@CIT0002]\]. In genotyping K741-K748 and K752-K753 were found to be clonally related (\>95%). Other isolates belong to different clone. Table 1.Clinical and laboratory characteristics of study population.CodeSTSourceColistin MICMeropenem MICCarbapenemaseEmpirical TherapyPre-exposure time to colistinActive TherapyDuration of Active Colistin TherapySurvival30-day MortalityClonal RelatednessK704235Catheter\>6416OXA-48, NDM-1Meropenem Vancomycin000Ex1 K741235BAL1616OXA-48, NDM-1Moxifloxacin0Meropenem Colistin Ertapenem1Ex2\*K7403078BAL\>648OXA-48, NDM-1Piperacillin Tazobactam0Meropenem Colistin Ertapenem27Ex30 K748235DTA6416OXA-48, NDM-10000DischargeDischarge\*K7523078DTA416OXA-48, NDM-10000DischargeDischarge\*\*K7533078BAL48OXA-48, NDM-1Piperacillin Tazobactam0Meropenem Colistin14DischargeDischarge\*\*K783235BAL1616OXA-48, NDM-1Meropenem Colistin10Meropenem Colistin10Ex7 K970235Catheter3216NDM-1Levofloxacin Colistin21 days00Ex10 K982235BAL1616OXA-48, NDM-1Colistin (inhalation)25 days00Ex1 K989235Catheter\>6416NDM-1Meropenem0Meropenem Colistin38Ex42 K1009235DTA1616OXA-48, NDM-1Colistin (inhalation)8 days00Ex19 Notes: BAL: Bronchoalveolar lavage; DTA: Deep tracheal aspirate.\*clone 1, \*\*clone 2.

All isolates were found to be carbapenem-resistant. All of them were NDM-1 positive, and nine (81.8%) harbour both OXA-48 and NDM-1 beta-lactamases. Carbapenem-resistant OXA-48 positive *P. aeruginosa* was isolated in Sudan and India \[[@CIT0011]\] and NDM-1 positive *P. aeruginosa* was detected in Serbia \[[@CIT0012]\]. However, this is the first report of co-existence of OXA-48 and NDM-1 producing *P. aeruginosa* isolation in Turkey and Europe.

Colistin use is one of the major factors responsible for the development of colistin resistance. In our study, only four patients (36,3%) received colistin therapy before the isolation of *P. aeruginosa* ([Table 1](#T0001){ref-type="table"}). The MICs for colistin were between 4 and \>64 mg/L. In all isolates, sequences of *pmrAB* and *phoPQ* revealed numerous insertions and deletions. In the ten of them, *pmrAB* and *phoPQ* were found to be upregulated. Relative expressions of *pmrA* and *phoQ* genes were between 0.3--59.9-fold (mean 12.9-fold) and 0.9-6.9-fold (mean 4.15-fold), respectively. In nine isolates, colistin MICs and *pmrAB*-*phoPQ* expressions were found to be related ([Figure 1](#F0001){ref-type="fig"}). These results suggested that there could be additional mechanisms contributing to colistin resistance in *P. aeruginosa*. Figure 1.*PmrA* and *PhoP* expressions of the colistin-resistant *P. aeruginosa* in correlation with colistin MIC values.

In conclusion, colistin resistance is emerging in *P. aeruginosa* ST235 global high-risk clone. The co-existence of OXA-48 and NDM-1 genes in colistin-resistant *P. aeruginosa* ST235 high-risk clone indicates the spread of carbapenemases in clinical isolates and highlights need of continuous surveillance for high-risk clones of *P. aeruginosa*.
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